Medpace Backs Phase 2 Cancer Imaging Trial With [68Ga]BED003
TipRanks (Wed, 15-Jul 12:31 PM ET)
Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026
Business Wire (Tue, 16-Jun 4:23 PM ET)
PRNewswire (Mon, 8-Jun 7:05 PM ET)
Business Wire (Mon, 8-Jun 4:48 PM ET)
Newsfile (Mon, 8-Jun 2:22 PM ET)
Globe Newswire (Mon, 8-Jun 2:00 PM ET)
Business Wire (Mon, 8-Jun 9:27 AM ET)
Globe Newswire (Sun, 7-Jun 5:55 PM ET)
Newsfile (Sun, 7-Jun 2:17 PM ET)
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Medpace Holdings trades on the NASDAQ stock market under the symbol MEDP.
As of July 15, 2026, MEDP stock price declined to $529.23 with 274,344 million shares trading.
MEDP has a beta of 1.25, meaning it tends to be more sensitive to market movements. MEDP has a correlation of 0.07 to the broad based SPY ETF.
MEDP has a market cap of $15.11 billion. This is considered a Large Cap stock.
Last quarter Medpace Holdings reported $707 million in Revenue and $4.28 earnings per share. This beat revenue expectation by $10 million and exceeded earnings estimates by $.41.
In the last 3 years, MEDP traded as high as $628.92 and as low as $227.21.
The top ETF exchange traded funds that MEDP belongs to (by Net Assets): IJH, VTI, VB, XMHQ, VBK.
MEDP has outperformed the market in the last year with a return of +65.2%, while the SPY ETF gained +22.0%. However, in the most recent history, MEDP shares have underperformed the stock market with its stock returning +1.8% in the last 3 month period and -0.1% for the last 2 week period, while SPY has returned +9.0% and +1.1%, respectively.
MEDP support price is $523.55 and resistance is $548.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MEDP shares will trade within this expected range on the day.